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.2011.12.0Abstract The aim of this study was to investigate the degree of correlation between the weight and
the content of spilt-halves of lorazepam 2.5 mg tablets. Weight variation and drug content of lor-
azepam half-tablets were evaluated according to the European Pharmacopoeia tests. Only one indi-
vidual mass of the 30 half tablets was outside the limits of 85–115% of the average mass, but since it
was within 75–125% of the average mass, the product passed the test. Each individual content was
between 85% and 115% of the average content (99.8% expressed as a percent to label claim) and
within the limits of 75–125%, so the product passed the uniformity of content test. The correlation
coefﬁcient (r) between the weight and the content of split halves was found to be 0.994. The weights
of split tablet halves appear to be directly correlated with their drug content even for a medication
with a low drug content, thus it is recommended that pharmacists who split tablets into two halves,
assure the weight uniformity of the resultant halves. Manufacturers should develop formulation and
manufacturing procedures that ensure high degree of correlation between weight and content not
only among the whole tablet but also among the obtained tablet halves.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
To ensure the consistency of dosage units, each unit in a given
batch should contain the active drug within a narrow range
around the label claim. The uniformity of dosage units can be
evaluated either by measuring the content uniformity or the
weight of the tested units (Green et al., 2009; The United States2345113; fax: +970 92345982.
.N. Zaid).
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09Pharmacopeial Convention, 2011). The test for weight variation
is applicable for hard capsules, uncoated tablets and ﬁlm-coated
tablets containing 25 mg or more of a drug substance compris-
ing 25% or more, by weight, of the dosage unit or, in the case
of hard capsules, the capsule contents, except that uniformity
of other drug substances present in lesser proportions is demon-
strated bymeeting the requirements for content uniformity. Un-
less the 25 mg/25% threshold limit is met, the use of the mass/
weight variation test as an alternative test for content uniformity
is not considered interchangeable in all International Confer-
ence onHarmonization (ICH) regions (The United States Phar-
macopeial Convention, 2011; International Conference on
Harmonization, 2008). The test for content uniformity is re-
quired for all dosage forms not meeting the above conditions
for the weight. These tests are necessary to ensure that patientsier B.V. All rights reserved.
72 A.N. Zaid et al.take a precise pharmaceutical dose. This issue is of high impor-
tance not only for whole tablets but also for the obtained halves
in cases of tablet splitting since the resultant splits are essentially
the new dosage form for the patient. In fact, tablet splitting is a
known, widely spread, and an accepted practice in the ﬁeld of
pharmacy. The reasons behind this practice include providing
the patient with the desired dose if the product is not available
in the required strength, starting therapy with the lowest possi-
ble doses to reduce the incidence of side effects of certain drugs,
reducing medication costs, and making the swallowing of large
tablets easier (Green et al., 2009; Duncan et al., 2002; Fawell
et al., 1999) Nevertheless, some problems may arise due to this
practice, the most important problem reported in this regard
is the poor weight and content uniformity of the obtained halves
(Kristensen et al., 1995; Zaid et al., 2010; Zaid andGhosh, 2011;
Cook et al., 2004; Teng et al., 2003; Polli et al., 2003). Uneven
splitting of a tablet productmay result in signiﬁcant ﬂuctuations
of the administered dose. This may be clinically signiﬁcant espe-
cially for drugs with a narrow therapeutic range (Vranic and
Uzunovic, 2007).
In 2002, the European Pharmacopoeia (Ph. Eur.) intro-
duced a new test on the accuracy of subdivision of scored tab-
lets (European Pharmacopoeia, 2002). Consequently, this test
has become a mandatory test in many European countries in
order to achieve uniform halves after tablet splitting and man-
ufacturers following the Ph. Eur. standards must consider
badly performing tablets as defective products (Van Santen
et al., 2002; Rodenhuis et al., 2003). The United States Phar-
macopeia (USP) and the British Pharmacopoeia (BP) contain
a quality control test regarding the weight uniformity of dos-
age units. However, they do not have tests regarding the
weight uniformity of the resultant split halves or the perfor-
mance of score lines of tablets. Several authors have advised
to add Pharmacopoeial standards for the subdivision charac-
teristics of scored tablets (Green et al., 2009; Rosenberg
et al., 2002; Zaid et al., 2012).
The aim of this study was to investigate degree of correlation
between the weight and the content of spilt-halves of lorazepam
2.5 mg tablets. Lorazepam 2.5 mg tablets were chosen because
lorazepam is a potent drug and the tablets will therefore contain
a small amount of drug, and because Benzodiazepines are
among the most commonly used classes of medications in the
ﬁeld of medicine. Their therapeutic actions as anxiolytics, seda-
tive hypnotics, anticonvulsants, and muscle relaxants have led
to their use as ﬁrst-line treatments. High-potency benzodiaze-
pines (e.g., alprazolam, clonazepam, and lorazepam) have re-
placed low and medium potency benzodiazepines in all
benzodiazepine clinical indications due to their greater thera-
peutic effects and rapid onset of action. Usually a maximum
dose of 2 mg/day of any of the high-potency benzodiazepines
when given for more than 1 week is recommended. Although
benzodiazepines act rapidly and are well tolerated medication
in general, still their long term use presents some clinical issues
such as dependence, rebound anxiety, memory impairment,
and discontinuation syndrome (Chouinard, 2004).2. Materials and methods
Lorazepam tablets (2.5 mg) were prepared by Pharmacare
PLC. The physical parameters of the obtained tablets were
evaluated. Weight variation and drug content of lorazepamhalf-tablets were evaluated according to the European Phar-
macopeia (Ph. Eur.). The target drug content and weight of
a half-tablet were deﬁned as equal to one-half of the mean
drug content and weight for whole tablets.
2.1. The European Pharmacopoeia test for uniformity of mass
The Ph. Eur. states: ‘‘Take 30 tablets at random and, from all
the parts obtained from 1 tablet, take 1 part for the test and
reject the other part(s). Weigh each of the 30 parts individu-
ally and calculate the average mass. The tablets comply with
the test if not more than 1 individual mass is outside the lim-
its of 85–115% of the average mass. The tablets fail to com-
ply with the test if more than 1 individual mass is outside
these limits, or if 1 individual mass is outside the limits of
75–125% of the average mass’’ (European Pharmacopoeia,
2008).
2.2. The European Pharmacopoeia test for uniformity of content
The Ph. Eur. states: ‘‘Subdivide 10 tablets and randomly select
10 parts from 10 subdivided tablets and, using a suitable ana-
lytical method, determine the content of active substance(s) in
each individual part. The preparation complies with the test if
each individual content is between 85% and 115% of the aver-
age content. The preparation fails to comply with the test if
more than one individual content is outside these limits or if
one individual content is outside the limits of 75–125% of
the average content. If one individual content is outside the
limits of 85–115% but within the limits of 75–125%, determine
the individual contents of another 20 units (subdivided tablet
parts) taken at random. The preparation complies with the test
if not more than one of the individual contents of the 30 units
is outside 85–115% of the average content and none is outside
the limits of 75–125% of the average content’’ (European
Pharmacopoeia, 2002).
2.3. Assay of lorazepam in tablet halves
For content evaluation, an HPLC system from Merck Hitachi,
(Interface module D-7000, Autosampler L-7200, Pump L-
7100, Detector L-7450) was used for the analysis and quantiﬁ-
cation of lorazepam in the samples studied. Separation was
accomplished using a 4.6-mm\25-cm column that contains 5-
lm packing L1 according to the USP 30 method (United
States Pharmacopeial Convention, 2007) (Table 1).
Microsoft Ofﬁce Excel 2007 was used to perform all related
calculations.
3. Results
Tablets were evaluated for physical parameters such as hard-
ness, friability, shape and diameter. These parameters were
within the accepted criteria for uncoated tablets with an aver-
age hardness of 4.9 KN, friability of 0.96%, average diameter
of 7.0 ± 0.3 mm.
The average mass of the 30 halves was 64.4 mg, only one
individual mass of the 30 half tablets was outside the limits
of 85–115% of the average mass (54.1 mg), but since it was
within 75–125% of the average mass, the product passed the
Ph. Eur. Test (Table 2).
Table 1 Summary of HPLC parameters for lorazepam assay.
Parameter Speciﬁcation
Column A 4.6-mm\25-cm column that contains
5-lm packing L1(C18)
Flow rate 1 mL/minute
Injection volume 20 lm
Wavelength 230 nm
Mobile phase Filtered and degassed mixture
of water, acetonitrile, and glacial
acetic acid (60:40:0.4)
Table 3 Results of uniformity of content test for lorazepam
2.5 mg, 10 halves.
Sample
Number
Content of lorazepam in each
unit of half tablet expressed as
a percent to label claim (%)
85–115% of the
average content
1 97.7 Yes
2 96.4 Yes
3 97.1 Yes
4 99.7 Yes
5 90.9 Yes
6 113.0 Yes
7 99.9 Yes
8 103.3 No
9 98.4 Yes
10 101.9 Yes
Average: 99.8 Yes
Result Pass
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ual content was between 85% and 115% of the average con-
tent (99.8% expressed as a percent to label claim) and within
the limits of 75–125%, so the product passed the uniformity
of content test (Table 3).
The correlation coefﬁcient (r) between the weight and the
content of split halves of lorazepam 2.5 mg was found to be
0.994.
4. Discussion
The main objective of any pharmacopeia is to provide the
manufacturers of drugs and pharmaceutical dosage forms with
a series of quality control tests (QC) that ensures high quality
of the ﬁnal obtained dosage forms. Most of these tests require
sophisticated instruments that cannot be found in community
pharmacies. Accordingly, pharmacists are unable to judge on
the quality of these dosage forms except for the visual QC or
weight uniformity of certain solid dosage forms such as tablets
and capsules. In fact, the content uniformity testing of a dos-
age unit is one of the Pharmacopoeial tests that are carried
out only in the QC departments of the industry or in laborato-
ries of the regulatory body as Ministry of Health (MOH).
Therefore, tablet products with high quality should be de-
signed and manufactured to have a high degree of correlationTable 2 Results of uniformity of mass tests for lorazepam 2.5 mg.
Sample
number
Weight of
half tablet
(g)
85–115% of
the average
mass
75–125% of
the average
mass
1 0.06510 Yes Yes
2 0.05810 Yes Yes
3 0.06871 Yes Yes
4 0.06740 Yes Yes
5 0.06780 Yes Yes
6 0.06400 Yes Yes
7 0.06410 Yes Yes
8 0.06862 Yes Yes
9 0.07012 Yes Yes
10 0.06920 Yes Yes
11 0.06510 Yes Yes
12 0.06310 Yes Yes
13 0.06600 Yes Yes
14 0.06420 Yes Yes
15 0.06320 Yes Yes
Average 0.0644
Result Passbetween the weight and content uniformity of the produced
tablets. This is done with the purpose of ensuring that patients
will take an accurate and precise dose of the medication. This
last objective is not necessarily realized if the tablet is split in
two halves to administer half of the labeled dose, especially
if the splitting process is not performed successfully to give
two equal halves or if the drug was distributed unevenly
throughout the tablet during its manufacture.
Several studies have been conducted to investigate the
weight uniformity of the obtained tablet halves (Kristensen
et al., 1995; Zaid et al., 2010; Zaid and Ghosh, 2011; Cook
et al., 2004). These studies have focused on weight uniformity
because this parameter should be correlated to the uniformity
of content which cannot be investigated using tools available
in a pharmacy setting. Weight uniformity of tablet halves can-
not be relied upon to achieve equal doses of drug in the resul-
tant splits when the tablets contain low amount of potent
active ingredient (PAI) such as the case of potent drugs. In
fact, the USP modiﬁed its weight uniformity test of tabletsSample
number
Weight of
half tablet
(g)
85–115% of
the average
mass
75–125% of
the average
mass
16 0.05930 Yes Yes
17 0.05560 Yes Yes
18 0.06660 Yes Yes
19 0.06320 Yes Yes
20 0.05810 Yes Yes
21 0.05410 No Yes
22 0.05800 Yes Yes
23 0.07100 Yes Yes
24 0.06500 Yes Yes
25 0.05820 Yes Yes
26 0.07000 Yes Yes
27 0.06810 Yes Yes
28 0.07100 Yes Yes
29 0.06800 Yes Yes
30 0.06100 Yes Yes
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less than 25% of the PAI. Unfortunately, the USP does not
have any test regarding the weight uniformity or the content
uniformity of the obtained tablet halves (Green et al., 2009).
The Ph. Eur. requires testing weight uniformity of tablet halves
but does not require any test with regard to their content uni-
formity. Accordingly, it is important to investigate the degree
of correlation between weight split halves of tablets and its
content uniformity as this would provide assurance to the
community pharmacist who performs the splitting process
for the patient. This is especially in cases of scored tablets that
contain very potent drugs such as lorazepam 2.5 mg/tablet.
This very low dose may easily result in the uneven distribution
of lorazepam throughout the tablets which later on leads to
ﬂuctuations of plasma drug levels even if the patient is taking
tablet halves with equal weights. Therefore, manufacturers
should develop high quality formulations and adopt manufac-
turing procedures that guarantee uniform distribution of the
active ingredient throughout the tablet product.
The results obtained in this study have shown that loraze-
pam 2.5 mg/tablet could pass both the weight uniformity and
the content uniformity of split halves. Additionally, a high de-
gree of correlation between the weights of the split tablet
halves and their lorazepam content has been seen. This is de-
spite the low weight, small size and low content of the tablets.
This study suggests that it is possible for manufacturers to
modify their formulation and manufacturing parameters in or-
der to improve this aspect of pharmacy practice.
For patients who practice tablet splitting, it is expected that
the quality of the medication is maintained after the tablet has
been split, including accurate medication dosage and desired
therapeutic effect. Drug content variation in half-tablets ap-
pears to be highly correlated to their weight variation. The cor-
relation coefﬁcient between the weight and the content of split
halves was 0.994. This result is similar to the ﬁndings of other
studies which have shown that drug content variation in half-
tablets appeared to be attributable primarily to weight varia-
tion occurring during the splitting process (Vranic´ and Uzuno-
vic´, 2007; Hill et al., 2009). Studies have shown that half tablets
are more likely to pass mass uniformity test if they have a suit-
able hardness, shape, and friability (Zaid and Ghosh, 2011;
Polli et al., 2003). Tablet manufacturers should be able to
determine the most appropriate size shape, friability and hard-
ness of tablets to facilitate proper splitting.
5. Conclusion
The weight of split tablet halves appears to be directly corre-
lated with their drug content, thus it is recommended that
pharmacists who split tablets into two halves, assure the
weight uniformity of the resultant halves since this may be
associated with content uniformity for these tablet halves.
Manufacturers should investigate the physical factors such as
tablet, size, shape, friability and hardness that may play an
important role in achieving both weight and content
uniformity.
Furthermore, manufacturers should develop formulation
and manufacturing procedures that ensure high degree of cor-
relation between weight and content not only among the whole
tablet but also among the obtained tablet halves.6. Conﬂict of interest
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